For the Inventor, By the Inventor

Enter assignee name

Mitsubishi Tanabe Pharma Corporation

Calculating rank

USPTO Granted Patents = 263

% Expired Patents = 62.0

CIPO Patents = 24

EPO Patents = 170

Trademarks = 18

Forward Citations = 693

Loading Chart...

Loading Chart...

510 inventors (with patents filed for the assignee):

Takayuki Kawaguchi (17 out of 43 patents)

Mourad Saady (15 out of 44 patents)

Alistair Lochead (15 out of 75 patents)

4. Philippe Yaiche (15 out of 43 patents)

5. Toru Iijima (14 out of 15 patents)

6. Sumihiro Nomura (14 out of 29 patents)

7. Kazutoshi Watanabe (12 out of 80 patents)

8. Maiko Hamada (12 out of 12 patents)

9. Hidenori Akatsuka (12 out of 12 patents)

10. Kenji Fukunaga (9 out of 18 patents)

11. Norimitsu Hayashi (9 out of 9 patents)

12. Hiroshi Sugama (9 out of 9 patents)

13. Eiji Kawanishi (8 out of 8 patents)

14. Osamu Sakurai (8 out of 8 patents)

15. Fumihiko Akahoshi (8 out of 10 patents)

Core Competencies:

Edaravone

Anti-IL-33

Pharmaceutical Composition

Chronic Fatigue Syndrome

Amyotrophic Lateral Sclerosis

Senescent Cells

Melanocortin Receptor Agonist

Renin Inhibitor

Vasomotor Symptoms

Ophthalmic Disease

Drug Conjugates

Syndecan-1

263 patents: Sort by Forward Citations

1. 12735705 - COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING EXPRESSION OF ATAXIN 3 (2026-09-15),

2. 12709750 - AGENT FOR PREVENTING OR TREATING MUSCULAR DISEASE (2026-08-18),

3. 12569455 - Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome (2026-03-10),

4. 12527769 - Pharmaceutical composition for oral administration of edaravone and method of administering same (2026-01-20),

5. 12516114 - HUMAN ANTI-IL-33 NEUTRALIZING MONOCLONAL ANTIBODY (2026-01-06),

6. 12503445 - Compounds and their use (2025-12-23),

7. 12478611 - Pharmaceutical composition for oral administration of edaravone and method of administering same (2025-11-25),

8. 12404247 - 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same (2025-09-02),

9. 12376781 - Brain wave analysis device, brain wave analysis system, and brain wave analysis program (2025-08-05),

10. 12338265 - Crosslinked artificial nucleic acid ALNA (2025-06-24),

11. 12320793 - Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient (2025-06-03),

12. 12310946 - Pharmaceutical composition for oral administration of edaravone and method of administering same (2025-05-27),

13. 12285409 - Edaravone suspension for oral administration (2025-04-29),

14. 12194025 - Pharmaceutical composition for oral administration of edaravone and method of administering same (2025-01-14),

15. 12102641 - Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof (2024-10-01),

Company Overview

Mitsubishi Tanabe Pharma Corporation, headquartered in Osaka, Japan, specializes in the development and manufacture of innovative pharmaceutical compositions. The company focuses on a range of therapeutic areas, including treatments for chronic fatigue syndrome and amyotrophic lateral sclerosis. Its research encompasses advanced technologies such as edaravone, anti-IL-33, and melanin receptor agonists, aiming to address complex health challenges and improve patient outcomes through targeted therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

263 Patents

#67 in Osaka

#588 in Japan

#3,343 in the World

Mitsubishi Tanabe Pharma Corporation

Forward Citations = 693

510 inventors:

Takayuki Kawaguchi (17 out of 43 patents)

Mourad Saady (15 out of 44 patents)

Alistair Lochead (15 out of 75 patents)

4. Philippe Yaiche (15 out of 43 patents)

5. Toru Iijima (14 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mitsubishi Tanabe Pharma Corporation. Retrieved from https://idiyas.com/company/mitsubishi-tanabe-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…